Thank you for your important research toward breakthroughs for people with Parkinson's and for your interest in working with The Michael J. Fox Foundation.
Below are MJFF’s open funding programs.
More information on our Application Guidelines can be found here, while information on proposal budgets and team composition can be found here in English and here in LATAM Spanish.
Email grants@michaeljfox.org with questions.
Browse Funding Opportunities
Open Programs
Open Programs
-
Collaborative Research Network (CRN) 2025 Opportunity
Objective:Aligning Science Across Parkinson’s (ASAP) is announcing two open competitive funding opportunities for the research community. These grants will provide additional capital to spur discovery for Parkinson’s disease (PD) research. -
The Edmond J. Safra Fellowship in Movement Disorders
Objective:The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.
Additional Funding Programs and Opportunities
The Michael J. Fox Foundation operates and collaborates with many programs that offer funding or support for researchers but are not presently open for general applications. These programs welcome specialized outreach and requests.
-
ASAP’s Collaborative Research Network (CRN)
The Aligning Science Across Parkinson’s Collaborative Research Network (ASAP CRN) is an international, multidisciplinary, and multi-institutional network of collaborating investigators working to address high-priority basic science questions in Parkinson’s disease.
-
ASAP’s Global Parkinson’s Genetics Program (GP2)
The Global Parkinson’s Genetics Program (GP2) is a resource program of the Aligning Science Across Parkinson’s initiative focused on improving our understanding of the genetic architecture of Parkinson’s disease and making this knowledge globally relevant.
-
Imaging Consortium
The Michael J. Fox Foundation maintains a pre-competitive consortium of industry collaborators to accelerate the development and availability of novel molecular imaging radiotracers for Parkinson's disease. The consortium supports tracer discovery, validation, and proof-of-concept studies for key Parkinson’s disease targets (such as dopamine and alpha-synuclein) and the strategic deployment of a subset of promising and validated tracers for use in multicenter clinical trials to advance therapeutics.
-
LRRK2 Investigative Therapeutics Exchange (LITE)
The LRRK2 Investigative Therapeutics Exchange (LITE) program aims to support new approaches to targeting LRRK2 with therapies, while also supporting the development of LRRK2-relevant clinical biomarkers to measure progress.
-
Parkinson’s Progression Markers Initiative (PPMI)
The Parkinson’s Progression Markers Initiative (PPMI) is a landmark study collaborating with partners around the world to create a robust open-access data set and biosample library to speed scientific breakthroughs and new treatments for Parkinson’s disease.
-
Path to Prevention (P2P)
The Path to Prevention (P2P) platform trial is designed to catalyze clinical development for prodromal Parkinson’s disease. P2P capitalizes on the infrastructure of the Parkinson’s Progression Markers Initiative (PPMI) to de-risk industry investments in pioneering therapies for individuals at risk of PD diagnosis.
-
Resources and Tools
The Michael J. Fox Foundation offers research support that goes beyond funding, including data, biospecimens and study recruitment assistance.
-
Targets to Therapies Initiative
The Targets to Therapies Initiative aims to expand the number of promising, druggable biological targets within the Parkinson’s disease translational pipeline. Leveraging The Michael J. Fox Foundation’s many years of experience supporting target validation and advancement, the initiative takes a fresh approach combining community-sourced target nomination with expert panel-guided prioritization and validation roadmaps to deliver targets that are ripe for Parkinson’s therapeutic development.
-
Grant Portal
View submitted or in progress applications.
-
Funding Alerts
Sign up for email updates on resources and initiatives to accelerate research and improve Parkinson's care.
